European Journal of Medicinal Chemistry Reports最新文献

{"title":"Targeted regulatory strategies for VCAM-1 in multisystem diseases","authors":"Ruirong Peng ,&nbsp;Yu Zhang ,&nbsp;Zhenyu He ,&nbsp;Yueling Pang ,&nbsp;Huanhuan Ma ,&nbsp;Ming Fang ,&nbsp;Xiaoshan Ding ,&nbsp;Yanan Wang ,&nbsp;Zhihong Du ,&nbsp;Fanming Kong ,&nbsp;Liping Chen ,&nbsp;Yongqi Liu ,&nbsp;Ling Li ,&nbsp;Jiawei Li","doi":"10.1016/j.ejmcr.2025.100300","DOIUrl":"10.1016/j.ejmcr.2025.100300","url":null,"abstract":"<div><div>Systemic diseases are conditions caused by multiple factors (such as immune disorders, inflammation, tumors, etc.) that affect multiple organs, tissues, or systems throughout the body. These diseases are typically characterized by complex pathological states and diverse clinical symptoms. Vascular cell adhesion molecule-1 (VCAM-1) is a multifunctional transmembrane protein that plays a key role in various pathological processes, including inflammation, immune responses, and tumor progression, by mediating immune cell adhesion, regulating the tumor microenvironment, and facilitating signal transduction. This article aims to review the mechanistic roles of VCAM-1 in systemic diseases affecting the circulatory, respiratory, and digestive systems, as well as the association between VCAM-1 and tumor characteristics. Additionally, it discusses targeted therapeutic drugs (including traditional Chinese medicine and Western medicine) that regulate VCAM-1 for disease treatment, providing a theoretical basis for clinical research.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100300"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Research progress of sustained-release microsphere technology in drug delivery","authors":"Tao-Tao Ge,&nbsp;Hai-Yan Guo,&nbsp;Chun-Mei Zhang,&nbsp;Shu-Feng Li","doi":"10.1016/j.ejmcr.2025.100299","DOIUrl":"10.1016/j.ejmcr.2025.100299","url":null,"abstract":"<div><div>sustained-release microsphere technology, with its unique advantages of prolonged controlled release, enhanced therapeutic efficacy, reduced side effects, and improved patient compliance, has emerged as a research hotspot in modern drug delivery. This review systematically summarizes recent advances in sustained-release microspheres in the biomedical field. First, the core concepts and distinct advantages of this approach, compared with conventional drug administration, are elaborated. Subsequently, the principles and features of key preparation techniques, including emulsion–solvent evaporation, spray drying, and advanced microfluidic methods, are highlighted. Furthermore, the applications and validation of microsphere-based systems in diverse therapeutic areas—such as transarterial chemoembolization for cancer, chronic disease management (e.g., diabetes, psychiatric disorders), and local targeted therapies (e.g., ophthalmology, postoperative analgesia)—are critically discussed. Finally, the current challenges and future perspectives of this technology are outlined, providing insights for its further development and clinical translation.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100299"},"PeriodicalIF":0.0,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145216488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protective effects of Sacha inchi meal protein hydrolysate against oxidative stress and endothelial dysfunction via MDA suppression and SOD activation in L-NAME-induced hypertensive rats","authors":"Pakaporn Sa-nguanpong ,&nbsp;Paweena Wetprasit ,&nbsp;Usana Chatturong ,&nbsp;Krongkarn Chootip ,&nbsp;Napapas Kantip ,&nbsp;Worasit Tochampa ,&nbsp;Khanitta Ruttarattanamongkol ,&nbsp;Tippaporn Bualeong","doi":"10.1016/j.ejmcr.2025.100297","DOIUrl":"10.1016/j.ejmcr.2025.100297","url":null,"abstract":"<div><div>Endothelial dysfunction and oxidative stress are central contributors to hypertension. Sacha inchi meal protein hydrolysate (SIPH) is recognized for its strong antioxidant activity and potential cardiovascular benefits. This study investigated the protective effects of SIPH on endothelial function and oxidative stress in rats with L-NAME (LN)-induced hypertension. Acute oral toxicity testing showed an LD₅₀ greater than 5000 mg/kg, classifying SIPH as low hazard (Category 5). Male Sprague-Dawley rats received LN (40 mg/kg) and were treated orally with SIPH (100, 300, or 500 mg/kg), captopril (5 mg/kg), or SIPH (500 mg/kg) combined with captopril (2.5 mg/kg) for five weeks. Blood pressure was monitored weekly and validated by carotid artery cannulation. Endothelial function was assessed by vasorelaxation responses to acetylcholine (ACh) and sodium nitroprusside (SNP) in isolated aortic rings, while serum malondialdehyde (MDA) and superoxide dismutase (SOD) activity were measured as markers of oxidative stress. LN administration elevated blood pressure impaired ACh-induced vasorelaxation, increased MDA, and reduced SOD activity. SIPH at 500 mg/kg significantly reduced blood pressure, restored endothelial-dependent relaxation, decreased lipid peroxidation, and enhanced antioxidant defense. Notably, the combination of SIPH with captopril exerted synergistic antihypertensive effects, producing greater improvements in vascular reactivity and oxidative balance than either treatment alone. These findings demonstrate that SIPH is a potent vascular protector, acting through synergistic antihypertensive, vasodilatory, and antioxidant mechanisms. Its properties position SIPH as a promising natural dietary intervention for mitigating hypertension and preserving endothelial function.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100297"},"PeriodicalIF":0.0,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145044692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of highly potent and selective oncogenic KRASG12D PROTAC degraders","authors":"Yaqiu Mao ,&nbsp;Pengli Wei ,&nbsp;Ting Wei ,&nbsp;Yalei Wang ,&nbsp;Zhenze Qi ,&nbsp;Xu Cai ,&nbsp;Changkai Jia ,&nbsp;Zhiyuan Zhao ,&nbsp;Bingkun Li ,&nbsp;Min Qiao ,&nbsp;Yaxin Zou ,&nbsp;Zhihui Mu ,&nbsp;Xiaofang Lei ,&nbsp;Tingting Yang ,&nbsp;Shiyang Sun ,&nbsp;Xuesong Feng ,&nbsp;Pengyun Li ,&nbsp;Zhibing Zheng","doi":"10.1016/j.ejmcr.2025.100296","DOIUrl":"10.1016/j.ejmcr.2025.100296","url":null,"abstract":"<div><div>As a key driver of tumorigenesis and cancer development, the KRAS^G12D mutation is ubiquitous existed in KRAS-associated malignancies, highlighting the urgent clinical need for effective KRAS^G12D targeting drugs. In this study, through rational design and multiple cell type-based antiproliferative evaluation, we identified a novel KRAS^G12D inhibitor, <strong>Y-I-1</strong>, which demonstrated remarkable anti-cancer activity. Subsequent computational analyses including molecular dynamics (MD) simulations, binding free energy calculations, umbrella sampling, and protein-ligand docking revealed its excellent binding characteristics, rationalizing the observed potency. Building upon the structure of <strong>Y-I-1</strong>, we constructed proteolysis-targeting chimera (PROTAC) by conjugating it with different linker moieties and VH032. Among them, degrader <strong>Y-D-2</strong> potently and selectively exhibited nanomolar inhibitory IC₅₀, degradation DC₅₀ values, and more than 95 % maximum degradation (D_max) in KRAS^G12D-mutant cancer cells via ubiquitin proteasome-involving pathway, accompanied by nanomolar IC₅₀ efficiency for phosphorylated ERK (pERK) inhibition. Mechanistically, <strong>Y-D-2</strong> significantly induced cell apoptosis, G1 cell cycle arrest and inhibited cell migration and invasion. Notably, <strong>Y-D-2</strong> led to significant tumor growth inhibition in the GP2D xenograft model with well-tolerated dose-schedules with favorable PK properties. This study not only provides an important theoretical basis for the optimal design of KRAS^G12D degraders, but also highlights its potential for the treatment of KRAS^G12D-driven cancers.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100296"},"PeriodicalIF":0.0,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecules with alkyne fragment in medicinal chemistry: The path from neurotoxins to drugs","authors":"Nataliya Zelisko ,&nbsp;Roman Lesyk","doi":"10.1016/j.ejmcr.2025.100294","DOIUrl":"10.1016/j.ejmcr.2025.100294","url":null,"abstract":"<div><div>In this comprehensive review, we explore a diverse array of highly promising compounds, categorized based on their pharmacological properties, origins, and synthetic methodologies, to highlight the critical role of alkyne functionalities in advancing medicinal chemistry. Our analysis underscores the unique contributions of acetylene-containing compounds, emphasizing their structural significance and therapeutic potential.</div><div>The remarkable versatility of acetylene-bearing molecules is evident in their wide-ranging biological activities, which position them as exceptional candidates for drug development. Extensive studies compiled in this review demonstrate that incorporating an acetylene group into molecular frameworks significantly enhances bioactivity. Numerous naturally occurring alkynes exhibit potent antibacterial, antifungal, and anticancer effects. Notably, compounds featuring a propargylamine group are established inhibitors of monoamine oxidase (MAO) and cholinesterases (ChEs). Additionally, a range of alkyne derivatives shows promise as H3-receptor antagonists, offering potential treatments for conditions such as epilepsy, depression, schizophrenia, Parkinson's disease, Alzheimer's disease, sleep disorders, attention deficit hyperactivity disorder, and various inflammatory and gastrointestinal disorders. Acetylene-containing compounds also play a role in anti-HIV therapies, with certain synthetic steroids falling within this class. Furthermore, alkynes are integral to multi-target-directed ligand (MTDL) strategies, broadening their therapeutic applications.</div><div>A particular focus of this review is the compelling anticancer potential of MAO inhibitors, which have garnered significant attention from pharmaceutical companies for their efficacy against prostate cancer, Hodgkin lymphoma, glioma brain tumors, non-small cell lung cancer, A-2058 melanoma cell lines, and acute myeloid leukemia. This has spurred interest in drug repurposing, establishing these compounds as a cornerstone of innovative therapeutic development.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100294"},"PeriodicalIF":0.0,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cheminformatics in advancing dengue antiviral research: From conventional molecular modeling (MM) to current artificial intelligence (AI) approaches","authors":"Rinki Prasad Bhagat ,&nbsp;Sk Abdul Amin ,&nbsp;Lucia Sessa ,&nbsp;Simona Concilio ,&nbsp;Stefano Piotto ,&nbsp;Shovanlal Gayen","doi":"10.1016/j.ejmcr.2025.100295","DOIUrl":"10.1016/j.ejmcr.2025.100295","url":null,"abstract":"<div><div>Cheminformatics has rapidly evolved and garnered widespread attention due to its potential to accelerate the process and reduce the cost of drug design and development. These technologies play a crucial role in drug design against dengue virus (DENV), a neglected tropical disease that remains a significant global health burden, with millions of cases reported annually. Recent advancements in cheminformatics and artificial intelligence (AI)-driven approaches offer promising strategies for designing inhibitors targeting key viral proteins. This study explores the applications of various cheminformatics methods, including conventional molecular modeling (pharmacophore mapping, molecular docking, molecular dynamics (MD) simulations, virtual screening), and artificial intelligence (AI)/machine learning (ML)-based strategies reported to identify compounds with high affinity and specificity for critical DENV protein targets. Additionally, it highlights the synergy between experimental validation, and <em>in silico</em> predictions to prioritize candidate molecules for further development.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100295"},"PeriodicalIF":0.0,"publicationDate":"2025-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144895363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening of G-quadruplex DNA ligands by fluorescence detection of peptide displacement","authors":"Valentina Arciuolo ,&nbsp;Simona Marzano ,&nbsp;Rossella Buono,&nbsp;Nicola Grasso,&nbsp;Anna Di Porzio,&nbsp;Antonio Randazzo,&nbsp;Bruno Pagano,&nbsp;Jussara Amato","doi":"10.1016/j.ejmcr.2025.100293","DOIUrl":"10.1016/j.ejmcr.2025.100293","url":null,"abstract":"<div><div>G-quadruplexes (G4s) are noncanonical DNA/RNA structures involved in key cellular processes, and their interactions with proteins are emerging as therapeutic targets. However, strategies to identify ligands that bind G4s and potentially modulate these interactions remain limited. Here, we describe a fluorescence-based assay for rapid, quantitative evaluation of small molecules that bind G4s and potentially interfere with protein recognition. The method employs a fluorophore-labeled peptide derived from a conserved G4-binding protein motif, and a G4-forming sequence labeled with a fluorescence acceptor. Ligand-induced peptide displacement is detected via fluorescence increase. A panel of known G4 ligands was tested, and results correlated with binding affinities. A duplex DNA competition assay further assessed ligand selectivity. This method provides a scalable tool for screening G4 ligands with ability to compete with G4-recognition motifs, supporting drug discovery efforts.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100293"},"PeriodicalIF":0.0,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual-target candidate compounds from a transformer chemical language model contain characteristic structural features","authors":"Sanjana Srinivasan ,&nbsp;Alec Lamens ,&nbsp;Jürgen Bajorath","doi":"10.1016/j.ejmcr.2025.100291","DOIUrl":"10.1016/j.ejmcr.2025.100291","url":null,"abstract":"<div><div>Chemical language models (CLMs) are increasingly used for generative design of candidate compounds for medicinal chemistry. However, their predictions are difficult to rationalize. Currently, detailed computational explanations of CLM-based compound generation are unavailable. Therefore, we have attempted to better understand from a medicinal chemistry perspective how CLMs learn and arrive at compound predictions. Therefore, we have subjected dual-target candidate compounds for polypharmacology generated with transformer CLMs to a series of analysis steps exploring structural features that are learned and compared them to known compounds with dual-target activity. Using machine learning combined with distinct chemical structure-oriented approaches from explainable artificial intelligence, we show that CLMs learn substructures characteristic of known dual-target compounds as a basis for generating new candidates with various chemical modifications.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100291"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel triazole-based coumarin compounds as acetylcholinesterase inhibitors: Evidence and mechanism of 3-acetyl coumarin tethered (2-bromophenyl)-1,2,3 triazole as a potential mixed type inhibitor","authors":"Naseer Ahmad Dar ,&nbsp;Owais Hassan Wani ,&nbsp;Yuanyuan Wang ,&nbsp;Faez Iqbal Khan ,&nbsp;Bilal A. Ganie ,&nbsp;Syed Wajaht A. Shah ,&nbsp;Tanveer Ali Dar ,&nbsp;Tabasum Ismail","doi":"10.1016/j.ejmcr.2025.100289","DOIUrl":"10.1016/j.ejmcr.2025.100289","url":null,"abstract":"<div><div>Acetylcholinesterase (AChE) inhibition remains an important therapeutic strategy for Alzheimer's diseases, prompting immense research for novel and efficient small-molecule inhibitors. In this context, the present study describes the synthesis, characterization and evaluation of novel ether-linked 3-acetyl triazole-substituted coumarin derivatives as potential AChE inhibitors. The synthetic route involved 3-acetyl-7-hydroxycoumarin preparation through the reaction of 2,4-dihydoxybenzaldehyde with ethyl acetoacetate. Following alkylation at hydroxyl group, the acetylated 7-hydroxycoumarin underwent 1,3-dipolar cycloaddition i.e., Huisgen cycloaddition with various aromatic azides under sharpless click chemistry conditions, leading to the formation of a library of 16 novel coumarin tethered 1,2,3-triazole derivatives. Following synthesis and characterization using ¹H NMR, ¹³C NMR and IR spectroscopy, the AChE inhibitory potential of the coumarin derivatives was assessed, yielding IC₅₀ value in the range of 2.18 μM–67.89 μM. Among them, compound <strong>9</strong> exhibited the most potent inhibition (IC₅₀ = 2.18 μM), although lower than that of the standard inhibitor, eserine. Kinetic analysis indicated that compound <strong>9</strong> acted as a mixed-type inhibitor, with a K_i of 8.13 ± 0.18 μM. <em>In silico</em> simulation analysis elucidated the critical interactions between compound <strong>9</strong> and key AChE residues, including hydrogen bonding with Tyr121 and His444 and π-π stacking with Tyr334 and Trp283, supporting its strong binding affinity for the enzyme. Furthermore, the binding free energy calculations also confirmed the favourable thermodynamic interactions between the compound <strong>9</strong> and AChE. Collectively, the present findings highlight the therapeutic potential of compound <strong>9</strong> and establish this novel coumarin-triazole scaffold as a promising lead candidate for further optimization in development of AChE-targeted Alzheimer's therapeutics.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100289"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In silico and In vitro profiling of lariciresinol against PLA2: A molecular approach to regulate inflammation","authors":"Fathimath Henna ,&nbsp;G. Arun Kumar ,&nbsp;Amritha Thaikkad ,&nbsp;T.K. Varun ,&nbsp;E. Jayadevi Variyar ,&nbsp;Rajesh Raju ,&nbsp;J. Abhithaj","doi":"10.1016/j.ejmcr.2025.100290","DOIUrl":"10.1016/j.ejmcr.2025.100290","url":null,"abstract":"<div><div>Chronic inflammation underlies various diseases, including cardiovascular disorders, cancer, and autoimmune conditions. Phospholipase A2 (PLA2) plays a central role in the inflammatory response by hydrolyzing membrane phospholipids to release arachidonic acid, a precursor for pro-inflammatory eicosanoids via the COX and LOX pathways. Due to its upstream regulatory function, PLA2 presents a strategic target for inflammation control. However, developing safe and effective PLA2 inhibitors remains challenging due to limitations in efficacy and side effects.</div><div>Natural compounds, particularly phytochemicals with anti-inflammatory potential, are gaining attention as alternative therapeutics. This study investigated Lariciresinol, a phenolic lignan from Zingiber officinale (ginger), for its inhibitory activity against PLA2. Selected through <em>in silico</em> screening, Lariciresinol was evaluated using molecular docking, molecular dynamics (MD) simulations, and <em>in vitro</em> enzyme inhibition assays. The compound showed competitive inhibition with an IC50 of 57.6μM. The binding energy of Lariciresinol improved from −24.71kcal/mol to −34.38kcal/mol after MD simulations. The results from the binding energy analysis and MD simulations revealed stable interactions with key catalytic residues, supporting its proposed mechanism of action.</div><div>Further <em>in silico</em> analysis of Root Mean Square Deviation, Root Mean Square Fluctuation, Radius of Gyration, H-bonds, Solvent Accessible Surface Area, and Free Energy Landscape validated the results. These results highlight Lariciresinol a promising scaffold for developing novel PLA2-targeted anti-inflammatory agents, warranting further <em>in vitro</em> and <em>in vivo</em> validation for clinical application.</div></div>","PeriodicalId":12015,"journal":{"name":"European Journal of Medicinal Chemistry Reports","volume":"15 ","pages":"Article 100290"},"PeriodicalIF":0.0,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144750757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}